Get your patients started with the AURYXIA Free Trial Program*

Looking for samples of AURYXIA?

Request Samples for your clinically appropriate patients

A male patient in a dark gray t-shirt sits with his forearms on his knees

Not actual patient.

Enrolled clinically appropriate patients will receive a FREE supply of AURYXIA sent directly to their home, along with helpful educational resources.

  1. Click the button below or go to to fill out the enrollment form

  2. Print and fax the form to 833-702-3436

Once your request is processed, AURYXIA will be shipped directly to your patients.

A male patient in a dark gray t-shirt sits with his forearms on his knees

Not actual patient.


*For patients new to AURYXIA and who have not previously enrolled in the program. This free trial prescription is valid for one time only with no refills. There is no obligation to continue use of AURYXIA after the free trial. If AURYXIA is right for your patient, a new prescription is needed to continue treatment. Terms and conditions apply.

Supplied in 1 bottle of 100-count 210 mg ferric iron tablets.




AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis


  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children


The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)


  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman


When clinically significant drug interactions are expected, e.g., Ciprofloxacin or Doxycycline, separate timing of administration.


AURYXIA® (ferric citrate) is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information